About DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals is a publicly listed company based in Seoul (South Korea) founded in 1984. Drugs are reformulated using transdermal delivery technologies. The company has 365 employees. Its website dhpharm.co.kr draws about 13 thousand monthly visits. DAE HWA Pharmaceuticals offers products and services including Prescription Drugs, OTC Drugs, and Health Functional Foods. Its focus areas include Life Sciences, Drug Delivery and Diversified. Its legal entity in India is λνμ μ½(μ£Ό) (U99999MH1977PLC010754).
Company details
DAE HWA Pharmaceuticals was founded in 1984 in Seoul, South Korea, and operates in the pharmaceutical sector. Focus is placed on reformulating existing drugs through transdermal and oral delivery methods. The lead product, DHP 107, an oral paclitaxel formulation, is undergoing phase III trials for cancer treatment. A lipid-based oral formulation has been developed, with plans to address NSAIDs, antihistamines, antidepressants, and additional medications.
- Headquarters Seoul, South Korea
- Employees 365
- Stage Public
- SectorsHealthcare
- Website dhpharm.co.kr/html
- Legal Name Dae Hwa Pharm Co., Ltd.
- Annual Revenue$99.06 M (USD)-4.25as on Dec 31, 2025
- Net Profit$1.14 M (USD)211.15as on Dec 31, 2025
- EBITDA$6.53 M (USD)-27.24as on Dec 31, 2025
- Employee Count365
Associated legal entities of DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals offers a comprehensive portfolio of products and services, including Prescription Drugs, OTC Drugs, and Health Functional Foods.
Medications for treatment under medical supervision.
Over-the-counter remedies for common health issues.
Supplements promoting health and wellness benefits.
IPO & Listings of DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals is a publicly listed company on the KRX with ticker symbol 067080 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Feb 2003
- Listed onKRX: 67080
- Listed entityDAE HWA PHARM Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7067080002
- Share price10,430.00 KRW (-3.43% on the day) · 2026-10-14
- Market capitalisation189,179,832,458.00 KRW
- Price to earnings41.8
- EPS (diluted, trailing year)249.29 KRW
- Dividend yield1.39%
- Volume (last session)138,729
Financials of DAE HWA Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 143.06B KRW | 1.65B KRW | 9.43B KRW |
| 2024 | 149.41B KRW | 531.4M KRW | 12.96B KRW |
| 2023 | 141.36B KRW | -1.15B KRW | 7.68B KRW |
| 2022 | 131.91B KRW | 1.12B KRW | 10.02B KRW |
| 2021 | 117.16B KRW | 2.22B KRW | 6.78B KRW |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for DAE HWA Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of DAE HWA Pharmaceuticals
The website of DAE HWA Pharmaceuticals (dhpharm.co.kr) receives about 13K visits a month.
- Monthly visits13K
▼ 6.8% vs previous month
Websites whose visitors overlap most with DAE HWA Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| connectdi.com | 100% | #1,644,654 | View details | ||
| mmpharm.co.kr | 98% | 25.5K | #769,589 | View details | |
| dhnp.co.kr | 90% | 9.1K | #1,796,932 | View details | |
kpanews.co.kr | kpanews.co.kr | 86% | #115,067 | β | |
yakup.com | yakup.com | 80% | #118,603 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 14 similar websites and full traffic analytics for DAE HWA Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dae Hwa Pharmaceuticals
Complete news archive for DAE HWA Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DAE HWA Pharmaceuticals
DAE HWA Pharmaceuticals was founded in 1984.
DAE HWA Pharmaceuticals is headquartered in Seoul, South Korea.
DAE HWA Pharmaceuticals has 365 employees.
Annual revenue of DAE HWA Pharmaceuticals is $99.06M as on Dec 31, 2025.
DAE HWA Pharmaceuticals was founded in 1984 in Seoul, South Korea, and operates in the pharmaceutical sector. Focus is placed on reformulating existing drugs through transdermal and oral delivery methods. The lead product, DHP 107, an oral paclitaxel formulation, is undergoing phase III trials for cancer treatment. A lipid-based oral formulation has been developed, with plans to address NSAIDs, antihistamines, antidepressants, and additional medications.
DAE HWA Pharmaceuticals offers Prescription Drugs, OTC Drugs, and Health Functional Foods.
Yes, DAE HWA Pharmaceuticals is publicly traded on KRX under the ticker symbol 067080.
DAE HWA Pharmaceuticals operates through ,.